ArticleGastrointestinal cancer research : GCR2009
Recent advances in the management of adenocarcinoma of the small intestine.
Article in Gastrointestinal cancer research : GCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2018Pooled it
- Role of Adjuvant Chemotherapy in Resected Small Bowel Adenocarcinoma: An Exploratory Real-World Analysis of Survival Outcomes and Prognostic Factors.Journal of clinical medicine · 2025Article
- Article
- Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia.Molecular and clinical oncology · 2023Article
- Early Discovery Of Small Bowel Adenocarcinoma In a Patient Admitted For 4 Acute Intestinal Intussusception.Annals of medicine and surgery (2012) · 2022Article
- Gastrointestinal Tract Microbiome Effect and Role in Disease Development.Diseases (Basel, Switzerland) · 2022Review
- Article
- Article
- Article
- Rare presentation of small bowel adenocarcinoma with neuroendocrine differentiation in the jejunum: A case report and summary of diagnostic and management options.Molecular and clinical oncology · 2019Article
- Diagnosis and Treatment of Synchronous Lymphoma and Digestive System Carcinoma: Report of Four Cases and Literature Review.Frontiers in oncology · 2019Article
- Intussuscepted Metachronous small bowel tumor after treatment for colorectal adenocarcinoma.International journal of surgery case reports · 2019Article
- ASO Author Reflections: Current Treatment Options for Duodenal Adenocarcinoma-A Call for Collaborative Studies.Annals of surgical oncology · 2018Article
- The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study.British journal of cancer · 2017Observational
- Clinicopathological features, surgical treatments, and survival outcomes of patients with small bowel adenocarcinoma.Medicine · 2017Article
- Small bowel adenocarcinoma in Lynch syndrome: A case report.Oncology letters · 2016Article
- Primary adenocarcinoma of the small intestine presenting as superior mesenteric artery syndrome: A case report.Oncology letters · 2016Article
- Adenocarcinoma of the ileum: A rare and challenging entity.Annals of medicine and surgery (2012) · 2015Article
- Adenocarcinoma of Small Bowel.Rare tumors · 2015Article
- Primary small-bowel malignancy: update in tumor biology, markers, and management strategies.Journal of gastrointestinal cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenocarcinoma of the small intestine is a rare malignancy with limited data available to guide therapeutic decisions. Delays in diagnosis are frequent and the majority of patients will present with advanced-stage disease and either lymph node involvement or distant metastatic disease. Furthermore, the role of adjuvant therapy in patients who undergo curative resection is unclear. Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma. The combination of capecitabine and oxaliplatin is highly active, with a median overall survival of 15 months in patients with metastatic disease. Further clinical studies in this rare tumor type are needed. This article reviews the clinical features and evaluation of patients with small bowel adenocarcinoma and focuses on recent advances in management.
Identifiers
19626152PMC2713134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.